SCHOTT Pharma, a pioneer in pharma drug containment solutions and delivery systems, has reported a solid performance in the third quarter of the fiscal year 2025.
“Our strong high-value solutions performance underscores the strength of our strategy built on innovation and trustful partnerships within the industry, even in a volatile market environment. This positions SCHOTT Pharma ideally to deliver solutions that meet the evolving needs of a dynamic, yet attractive market,” said Andreas Reisse, CEO of SCHOTT Pharma.
Highlights
- Q3 2025 revenues up 1 percent yoy to EUR 256m; increase of 3 percent yoy at constant currencies
- Q3 2025 EBITDA margin of 32.4 percent as reported and 31.7 percent at constant currencies
- Share of strong-margin high-value solutions (HVS) at 60 percent in Q3 2025
- Organic revenue growth for FY 2025 is expected to be around 6.0 percent
- The EBITDA margin for FY 2025 is expected to be around 28.0 percent
New CFO appointed
Starting August 1, 2025, SCHOTT Pharma has welcomed Reinhard Mayer as its new Chief Financial Officer. Mayer brings with him a wealth of experience in corporate finance, controlling, and IT, including more than 20 years in CFO positions, most recently at Denmark-listed Nilfisk Holding A/S.
Expressing his enthusiasm for joining SCHOTT Pharma, Reinhard Mayer said, “I’m eager to drive the company’s success story in the coming years and build upon this strong foundation with the SCHOTT Pharma team.” His leadership is expected to enhance the company’s strategic financial direction and reinforce its robust market position.
The full report is available here.